test announcement
Consider umeclidinium as first choice for patients with moderate or severe COPD (FEV1 60% or less and frequent exacerbations and breathlessness). Stop ipratropium if a long-acting antimuscarinic bronchodilator is started. Assess after 2 months and discontinue if no improvement. Advise patients that dry mouth is a frequent side-effect.
PREFERRED: Dry Powder Inhaler (DPI) (Inhalation powder)These are more environmentally friendly than MDIs and should be considered first line providing that the patient shows good inhaler technique with the chosen device.
COPD, by inhalation of powder: 1 inhalation once daily.
PREFERRED: Dry Powder Inhaler (DPI) (Inhalation powder)These are more environmentally friendly than MDIs and should be considered first line providing that the patient shows good inhaler technique with the chosen device.
COPD, by inhalation of powder: 18 micrograms (1 capsule) once daily.
PREFERRED: Soft Mist Inhaler (SMI) These are more environmentally friendly than MDIs and should be considered first line providing that the patient shows good inhaler technique with the chosen device.
COPD, by inhalation of aerosol (Spiriva® Respimat®), 5 micrograms (2 puffs) once daily.
As per SMC 411/07: as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
PREFERRED: Dry Powder Inhaler (DPI) (Inhalation powder)These are more environmentally friendly than MDIs and should be considered first line providing that the patient shows good inhaler technique with the chosen device.
COPD, by inhalation of powder: 1 inhalation twice daily.
TAM (Treatments and Medicines) NHS Highland